Please login to the form below

Not currently logged in
Email:
Password:

acalabrutinib

This page shows the latest acalabrutinib news and features for those working in and with pharma, biotech and healthcare.

AZ’s BTK inhibitor Calquence fails in COVID-19 study

AZ’s BTK inhibitor Calquence fails in COVID-19 study

The CALAVI phase 2 trials had been evaluating the efficacy and safety of Calquence (acalabrutinib) alongside best supportive care (BCS) in patients hospitalised with respiratory complications of COVID-19.

Latest news

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....

Infographics